Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK.

Slides:



Advertisements
Similar presentations
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Advertisements

Funding to Oxford University for MRC/BHF Heart Protection Study Medical Research Council$14M British Heart Foundation$2M Merck $8M Roche Vitamins$8M Designed,
The results of the Study of Heart and Renal Protection (SHARP)
SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.
Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.
The results of the Study of Heart and Renal Protection (SHARP) Colin Baigent, Martin Landray on behalf of the SHARP Investigators Disclosure: SHARP was.
HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.
HPS2-THRIVE: Treatment of HDL to Reduce the Incidence of Vascular Events Jane Armitage on behalf of the THRIVE Collaborative Group Financial Disclosure:
HPS2-THRIVE: Randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Jane Armitage.
Lipid Disorders and Management in Diabetes
Challenges When Conducting Economic Evaluation Alongside Clinical Trials: Experience Of Economic Appraisal In Cardiovascular Disease Andrew Briggs University.
The efFects of Pharmacological management of lipids in patients with CKD Andrew Monson FY1 18/9/14.
Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Cholesterol quintile (mg/dL)
IHS SDPI COMPETITIVE GRANT PROGRAM CVD RISK REDUCTION DEMONSTRATION PROJECT WHAT IS THE EVIDENCE? HOW ARE WE DOING? HOW CAN WE DO BETTER? Karl Hammermeister,
CHOLESTEROL LOWERING.
COMMIT/CCS-2 (ClOpidogrel & Metoprolol in Myocardial Infarction Trial)
Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Plasma Homocysteine and Coronary Heart Disease David S. Rosenblatt, MD Department of Human Genetics McGill University.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,
Antithrombotic Trialists’ (ATT) Collaboration. Lancet 2009;373:
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
4S: Scandinavian Simvastatin Survival Study
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Baseline characteristics of participants presenting with or without peripheral artery disease (PAD) Heart Protection Study Group J Vasc Surg 2007;45:
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
ELIGIBILITY: MRC/BHF Heart Protection Study Increased risk of CHD death due to prior disease: Myocardial infarction or other coronary heart disease; Occlusive.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial
Baseline characteristics of HPS participants by prior cerebrovascular disease.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from participants in 26 randomised trials Lancet 2010;
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
Title slide.
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Funding to Oxford University for MRC/BHF Heart Protection Study
Economic evaluation of MRC/BHF Heart Protection Study
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Effects of Anacetrapib on the Incidence of New-Onset Diabetes Mellitus and on Vascular Events in People With Diabetes Louise Bowman & Martin Landray on.
Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.
The Anglo Scandinavian Cardiac Outcomes Trial
ELIGIBILITY: MRC/BHF Heart Protection Study
AIM HIGH Niacin plus Statin to prevent vascular events
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Baseline characteristics of HPS participants by prior diabetes
The Hypertension in the Very Elderly Trial (HYVET)
The results of the SHARP trial
ELIGIBILITY: MRC/BHF Heart Protection Study
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Baseline Characteristics by Baseline N-BNP Level
Heart Protection Study Collaborative Group Lancet 2011;377:469-76
Estimated 5-year rate of a first major vascular event (MVE), major coronary event (MCE),or vascular death in univariate and multivariate risk subgroups.
Cause of death Treatment-arm events, % (n=45 054)
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.
The results of the SHARP trial
PROSPER: trial design                                                                                                                                                                 
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Presentation transcript:

Economic evaluation of MRC/BHF Heart Protection Study Heart Protection Study Collaborative Group University of Oxford UK

HPS: Eligibility criteria Increased risk of CHD death due to prior disease: Myocardial infarction or other CHD; Occlusive disease of non-coronary arteries; or Diabetes mellitus or treated hypertension Age years Total cholesterol  3.5 mmol/l (  135mg/dl) Statin or vitamins not considered clearly indicated or contraindicated by patient’s own doctors

Cost-effectiveness analysis of allocation to 40mg daily simvastatin Based on within trial period only (mean 5 years) Costs for UK National Health Service (2001) Cost-effectiveness analyses undertaken: –per major vascular event* avoided –per vascular death avoided –overall and in subgroups at differing absolute risk *first or subsequent heart attack, stroke or revascularisation following randomisation

Major vascular events (MVE) and vascular deaths per 1000 patients Simvastatin allocated Placebo allocated Avoided per 1000 (SE) All MVE (10) Vascular death (4)

HPS: Methods of calculating costs Costs included Study simvastatin (40mg daily at £1/day) and any non-study statin Hospitalisations for all major and other vascular events Costs excluded Non-statin drugs Hospitalisations for non-vascular events (no significant differences between groups) Primary and social care costs (no data available in HPS )

Mean costs per patient for statin use and hospitalisation for any vascular event Cost category Simvastatin (n = 10,269) Placebo (n = 10,267) Difference (SE) Statin use £1,712 £215 £1,497 (8) Vascular events £1,819£2,319-£500 (78) Total£3,530£2,534£996 (79)

Cost per MVE avoided: £11,000 (£8-16,000) Cost per vascular death avoided: £66,000 (£42-135,000) Overall cost-effectiveness within trial (95% CI)

Assessing subgroup effects reliably Analyses in different subgroups indicate: –Similar relative reduction in vascular events –Similar relative reduction in costs of vascular events –Similar absolute difference in statin treatment cost Hence, cost-effectiveness for subgroups estimated by applying overall treatment effects to placebo event rates and costs observed in each subgroup

Cox model on baseline characteristics used to create 5 multivariate risk groups Risk Group Number5-yr risk MVE 5-yr risk MCE 5-yr risk vascular death % 18% 23% 28% 42% 4% 7% 10% 13% 22% 3% 5% 7% 10% 18%

Similar relative reduction in first MVE by prior disease and age SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) Prior disease Any CHD21.8%27.5% No prior CHD CVD18.7%23.6% PVD24.7%30.5% Diabetes13.8%18.6% Age (years) <6516.9%22.1% ≥65 <7020.9%27.2% ≥7023.6%28.7% ALL PATIENTS19.8%25.2% 24% SE 3 reduction (2P< )

Similar relative reduction in first MVE by LDL & HDL SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Baseline feature (10269)(10267) LDL Cholesterol (mmol/l) < %22.2% ≥3.0 < %25.7% ≥ %27.2% HDL Cholesterol (mmol/l) < %29.9% ≥0.9 < %25.1% ≥ %20.9% ALL PATIENTS19.8%25.2% 24% SE 3 reduction (2P< )

Similar relative reduction in first MVE by risk group SIMVASTATINPLACEBORate ratio & 95% CI STATIN betterPLACEBO better Risk group (10269)(10267) 1 (low risk)8.3%11.8% 213.9%18.2% 318.4%24.9% 424.5%29.6% 5 (high risk)33.8%41.4% ANY OF ABOVE19.8%25.2% 24% SE 3 reduction (2P< )

Similar relative reduction in costs (£) of all vascular events by prior disease and age STATINPLACEBOBaseline feature Prior disease Any CHD No prior CHD CVD PVD Diabetes  2 3 =0.8 Age < >  2 2 =0.8 ALL PATIENTS ( )

Similar relative reduction in costs (£) of all vascular events by risk group STATINPLACEBORisk group 1 (low risk) (high risk)  2 4 =4.0 ALL PATIENTS ( )

Similar absolute difference in statin costs by risk group Statin costs (£) Difference£1555£1536£1534£1485£1371 (SE)(16)(17) (19) S P S P S P S P S P Risk group

Similar absolute difference in statin costs by disease and age Statin costs (£) Difference£1494£1503£1494£1514£1488 (SE)(10)(12)(11)(16)(14) S P S P S P S P S P Prior disease No CHD Any CHD < 65 ≥ 65 < 70 ≥ 70 Age (years)

Vascular event cost-savings by risk group 100% 50% % Current simvastatin price 25% 12% 5-yr risk MVE 42% 5-yr risk MVE

50% Vascular event cost-savings by risk group 100% % Current simvastatin price 25% 12% 5-yr risk MVE 42% 5-yr risk MVE

50% 25% Vascular event cost-savings by risk group 100% % Current simvastatin price 12% 5-yr risk MVE 42% 5-yr risk MVE

Cost per MVE avoided by risk group Overall: £11,000 12% 5-yr risk MVE 42% 5-yr risk MVE

Cost per vascular death avoided by risk group Overall: £66,000 12% 5-yr risk MVE 42% 5-yr risk MVE

On-going health economic analyses Extrapolation to effects beyond trial period Assessment of cost per QALY Adapt analyses to other countries

CONCLUSIONS: Economic evaluation of HPS Simvastatin allocation reduced vascular hospitalisation costs by 22% regardless of patient characteristics Cost-effectiveness is chiefly determined by an individual’s overall risk of vascular events (rather than by single risk factors, such as LDL) Statin treatment is cost-effective for a wide range of high-risk individuals (and will become increasingly so as statin prices fall)